CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Clinical trial NCT03448393 · COMPLETED

Trial details

NCT number: NCT03448393
Sponsor: National Cancer Institute (NCI)
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, B Cell B-Cell Lymphoma B-Cell Leukemia Acute Lymphoid Leukemia B-Non Hodgkin Lymphoma B-NHL B-All Acute Lymphoblastic Leukemia Acute Lymphocytic Leukemia

Start date: 2018-03-26
Primary completion: 2024-07-10
Enrollment: 54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.